Generic Epsolay Availability
Last updated on Apr 10, 2025.
Epsolay is a brand name of benzoyl peroxide topical, approved by the FDA in the following formulation(s):
EPSOLAY (benzoyl peroxide - cream;topical)
-
Manufacturer: GALDERMA LABS LP
Approval date: April 22, 2022
Strength(s): 5% [RLD]
Is there a generic version of Epsolay available?
No. There is currently no therapeutically equivalent version of Epsolay available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Epsolay. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Method for treatment of rosacea in patients aged 65 years and older
Patent 10,933,046
Issued: March 2, 2021
Inventor(s): Toledano Ofer & Levy-Hacham Ofra & Nov Ori & Ram Vered
Assignee(s): SOL-GEL TECHNOLOGIES, LTD.A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.
Patent expiration dates:
- February 19, 2040✓✓
- February 19, 2040
-
Method for providing early onset of action in the treatment of rosacea
Patent 10,945,987
Issued: March 16, 2021
Inventor(s): Toledano Ofer & Levy-Hacham Ofra & Nov Ori & Ram Vered
Assignee(s): SOL-GEL TECHNOLOGIES LTD.A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.
Patent expiration dates:
- February 19, 2040✓
- February 19, 2040
-
Method for long-term treatment of rosacea
Patent 11,426,378
Issued: August 30, 2022
Inventor(s): Toledano Ofer & Levy-Hacham Ofra & Nov Ori & Ram Vered
Assignee(s): SOL-GEL TECHNOLOGIES LTD.A regimen for the long-term therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in the pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75%.
Patent expiration dates:
- August 18, 2040✓
- August 18, 2040
-
Method for treatment of rosacea
Patent 11,541,026
Issued: January 3, 2023
Inventor(s): Arkin; Moshe et al.
Assignee(s): SOL-GEL TECHNOLOGIES LTD. (Ness Ziona, IL)A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.
Patent expiration dates:
- February 19, 2040✓
- February 19, 2040
-
Method for therapeutic treatment of rosacea
Patent 11,628,155
Issued: April 18, 2023
Inventor(s): Toledano; Ofer et al.
Assignee(s): SOL-GEL TECHNOLOGIES LTD. (Ness Ziona, IL)A regimen and a pharmaceutical composition for the treatment of rosacea are described. The regimen includes topically applying to the skin of a subject in need of such treatment a pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and the pharmaceutically acceptable carrier or excipient, where the benzoyl peroxide is the only active ingredient in the pharmaceutical composition, and the pharmaceutical composition is a cream or an emulsion.
Patent expiration dates:
- December 27, 2040✓
- December 27, 2040
-
Method for treatment of rosacea in patients aged 65 years and older
Patent 11,865,100
Issued: January 9, 2024
Inventor(s): Toledano; Ofer et al.
Assignee(s): Sol-Gel Technologies Ltd. (Ness Ziona, IL)A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.
Patent expiration dates:
- February 19, 2040✓
- February 19, 2040
-
Method for providing early onset of action in the treatment of rosacea
Patent 11,877,997
Issued: January 23, 2024
Inventor(s): Toledano; Ofer et al.
Assignee(s): Sol-Gel Technologies Ltd. (Ness Ziona, IL)A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.
Patent expiration dates:
- February 19, 2040✓
- February 19, 2040
-
Method for treatment of rosacea
Patent 11,986,456
Issued: May 21, 2024
Inventor(s): Arkin; Moshe et al.
Assignee(s): Sol-Gel Technologies Ltd. (Ness Ziona, IL)A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.
Patent expiration dates:
- February 19, 2040✓
- February 19, 2040
-
Method for preparing particles comprising metal oxide coating and particles with metal oxide coating
Patent 12,156,946
Issued: December 3, 2024
Inventor(s): Toledano; Ofer et al.
Assignee(s): Sol-Gel Technologies Ltd. (Ness Ziona, IL)The invention relates to a process for coating a solid, water-insoluble particulate matter, with a metal oxide comprising: (a) contacting the solid, water-insoluble particulate matter with an ionic additive and an aqueous medium to obtain a dispersion of said particulate matter having positive charges on its surface; (b) subjecting the particulate matter to a coating procedure comprising precipitating a metal oxide salt onto the surface of the particulate matter to form a metal oxide layer thereon to thereby obtain particulate matter coated by a metal oxide coating layer; (c) repeating step (b) at least 4 more times; and (d) aging said coating layer. The invention further relates to particles comprising a particulate matter coated by a metal oxide layer, to a use of the particles for topical administration, and to a method for preventing, reducing, or eliminating pests at a locus, using the particles.
Patent expiration dates:
- February 3, 2028✓
- February 3, 2028
-
Compositions for the treatment of rosacea
Patent 9,687,465
Issued: June 27, 2017
Inventor(s): Sertchook Hanan & Toledano Ofer & Bar-Simantov Haim
Assignee(s): SOL-GEL TECHNOLOGIES LTD.The present invention relates to pharmaceutical compositions for topical use (including also dermatological compositions), for treating skin conditions and afflictions, such as rosacea and symptoms and conditions associated there from.
Patent expiration dates:
- November 27, 2032✓✓
- November 27, 2032
-
Metal oxide coating of water insoluble ingredients
Patent 9,868,103
Issued: January 16, 2018
Inventor(s): Toledano Ofer & Sertchook Hanan & Loboda Natalia & Bar-Simantov Haim
Assignee(s): SOL-GEL TECHNOLOGIES LTD.The invention relates to process for coating a solid, water-insoluble particulate matter, with a metal oxide comprising: (a) contacting the solid water-insoluble particulate matter with a cationic additive in an aqueous medium to obtain a dispersion of said particulate matter having a positive zeta potential; (b) coating the solid water-insoluble particulate matter by precipitation of a metal oxide salt onto the surface of the particulate matter, forming a metal oxide layer thereon; and (c) aging said coating layer. The invention further relates to coated particulate matter obtained by the process and to compositions comprising solid, water-insoluble particulate matter, coated by a metal oxide layer, the particulate matter being a dermatological active agent or a pesticide. The invention additionally relates to methods of treating a surface condition in a subject using compositions comprising solid, water insoluble dermatologically active agent, coated by a metal oxide layer.
Patent expiration dates:
- August 8, 2028✓✓
- August 8, 2028
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 22, 2025 - NEW PRODUCT
More about Epsolay (benzoyl peroxide topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: topical acne agents
- Breastfeeding
- En español
Patient resources
Other brands
Benzac, Acne-Clear, Oxy-10, PanOxyl, ... +37 more
Professional resources
Other brands
Enzoclear Foam, BenzePro, BPO 6 Foaming Cloths
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
